Nuvalent Inc. (NUVL)
82.18
1.92 (2.39%)
At close: Feb 20, 2025, 3:59 PM
82.39
0.26%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 80.11 |
| Market Cap | 5.84B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.49 |
| PE Ratio (ttm) | -23.55 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 84.67 |
| Volume | 229,656 |
| Avg. Volume (20D) | 460,567 |
| Open | 80.26 |
| Previous Close | 80.26 |
| Day's Range | 79.11 - 82.40 |
| 52-Week Range | 61.80 - 113.51 |
| Beta | undefined |
About NUVL
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 29, 2021
Employees 127
Stock Exchange NASDAQ
Ticker Symbol NUVL
Website https://www.nuvalent.com
Analyst Forecast
According to 11 analyst ratings, the average rating for NUVL stock is "Buy." The 12-month stock price forecast is $110, which is an increase of 33.85% from the latest price.
Buy 90.91%
Hold 9.09%
Sell 0.00%
5 months ago
-6.61%
Nuvalent shares are trading lower after the compan...
Unlock content with
Pro Subscription
5 months ago
+28.27%
Nuvalent shares are trading higher after the company highlighted results for its ROS1 and ALK-Positive NSCLC programs and accelerated its development timeline. Also, the company announced a $350 million public offering and multiple firms raised their respective price targets on the stock.
